Tyra Biosciences Inc (TYRA)
Tyra Biosciences Inc. is a clinical-stage biotechnology company focused on precision medicines targeting fibroblast growth factor receptor, or FGFR, biology. Based in Carlsbad, California, the company uses its SNÃ…P precision medicine platform to support drug design through iterative molecular snapshots intended to help anticipate genetic alterations relevant to oncology and genetically defined conditions. Its clinical pipeline includes FGFR3, a lead product candidate being evaluated for metastatic urothelial carcinoma and other solid tumors. Tyra Biosciences is also advancing TYRA-300 for skeletal conditions such as achondroplasia, hypochondroplasia, dysplasia, and other FGFR3-driven genetic syndromes, as well as TYRA-200 for intrahepatic cholangiocarcinoma and TYRA-430 for hepatocellular carcinoma. The company was incorporated in 2018 and trades on NASDAQ as common stock.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-TYRA
|
$25.84
|
-17.9% Downside
|
Fair
|
$51.97
|
65.2% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 6, 2026
|
-14.2x
|
4.8x
|
—
|
1.847 B
|
1.488 B
|
0.3%
|
52.0%
|
43.9
|
—
|
78.2%
|
